Maravai Lifesciences Holdings (MRVI) Capital Expenditures (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Capital Expenditures of $4.4 million for Q1 2026, up 209.41% year-over-year from $1.4 million in Q1 2025, and down 63.73% quarter-over-quarter from $12.2 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Capital Expenditures (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Capital Expenditures history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 209.41% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $16.2 million (up 1718.92% YoY), while the FY2025 annual figure was $13.1 million, up 402.64% from the prior year.
- Capital Expenditures for Q1 2026 stood at $4.4 million, down from $12.2 million in the prior quarter.
- The five-year high for Capital Expenditures was $25.1 million in Q2 2023, with the low at -$46.7 million in Q4 2023.
- The 5-year median for Capital Expenditures is $4.4 million (2026), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures soared 1697.01% in 2022, then sank 409.46% in 2023.
- Maravai Lifesciences Holdings' Capital Expenditures stood at -$9.2 million in 2022, then tumbled by 409.46% to -$46.7 million in 2023, then soared by 54.66% to -$21.2 million in 2024, then surged by 157.72% to $12.2 million in 2025, then plunged by 63.73% to $4.4 million in 2026.
- Business Quant data shows MRVI's Capital Expenditures at $4.4 million in Q1 2026, $12.2 million in Q4 2025, and -$7.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 370,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 370,000.00 |
| Jun 30, 2026 | 370,000.00 |
| Mar 31, 2026 | 4.44 Mn |
| Mar 31, 2026 | 4.44 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Sep 30, 2025 | -7.19 Mn |
| Sep 30, 2025 | -7.19 Mn |
| Jun 30, 2025 | 6.68 Mn |
| Jun 30, 2025 | 6.68 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Dec 31, 2024 | -21.19 Mn |
| Dec 31, 2024 | -21.19 Mn |
| Sep 30, 2024 | 8.59 Mn |
| Sep 30, 2024 | 8.59 Mn |
| Jun 30, 2024 | 12.06 Mn |
| Jun 30, 2024 | 12.06 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Mar 31, 2024 | 3.16 Mn |